Karyopharm Therapeutics
Steve Mitchell is a seasoned medical writer with extensive experience in scientific communication. Currently serving as Principal Medical Writer at Karyopharm Therapeutics Inc. since January 2022, responsibilities include developing and managing the publication process for scientific manuscripts and presentations. Previous roles include Medical Writer at Merz Aesthetics, where high-quality content was created for various scientific communications, and Managing Editor/Technical Specialist at ICF, overseeing the Alcohol Research: Current Reviews journal. Earlier experience also includes senior medical writing positions at MedStar Health, extensive journalism roles at Consumer Reports and United Press International, and writing for health outlets such as WebMD and Reuters. Steve holds a Master's degree in Physiology from Virginia Commonwealth University and a Bachelor's degree in Biology from Virginia Tech, supplemented by a Full Stack Web Development Certification.
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).